mounjaro pregnancy safety tirzepatide (Tirzepatide) for Medical Weight Loss in Fayetteville, NC Mounjaro (Tirzepatide) Side Effects: Your

Oral semaglutide options may also trigger less anxiety due to slower systemic absorption compared to injections, making the switch clinically reasonable if anxiety persists

Common (usually temporary) Nausea, fullness, decreased appetite Heartburn, burping, mild constipation or diarrhea Fatigue, headache, injection-site tenderness Less common Gallbladder issues (rare) Pancreatitis symptoms (severe abdominal painseek care) Allergic reaction (stop and contact provider) Who should avoid/ use caution Personal/family history of medullary thyroid carcinoma (MTC) MEN2 (Multiple Endocrine Neoplasia syndrome type 2) Active pancreatitis, severe GI disease, or pregnancy *This is educational and not medical advice

Pre-existing risk factors for gallstone disease include: Female sex : Women are two to three times more likely to develop gallstones than men, particularly during reproductive years due to hormonal influences Age over 40 years : Gallstone prevalence increases progressively with age Obesity : Higher body mass index correlates with increased gallstone risk, creating a paradox where the condition being treated is itself a risk factor Rapid weight loss history : Previous episodes of quick weight reduction may indicate susceptibility Pregnancy or recent pregnancy : Hormonal changes affect bile composition and gallbladder motility Family history : Genetic factors contribute to gallstone formation Certain ethnicities : Native American and Hispanic populations have higher gallstone prevalence Metabolic syndrome and diabetes : These conditions are associated with altered bile metabolism The rate and magnitude of weight loss during semaglutide treatment significantly influence gallbladder complication risk

Dr Rothwell has received honoraria for advisory board or trial committee participation from Abbott, Bayer, and Bristol Myers Squibb

Are you hydrated

This genetic context may help provide insights into your baseline GLP-1 pathway activity and metabolic efficiency, supporting a more informed conversation with your healthcare provider about semaglutide risk tolerance and dosing strategy